Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome.
Prasad
Abhiram
A
Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn, USA.
Quyyumi
Arshed A
AA
D000273:Adipose Tissue / Q000503:physiopathology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000809:Angiotensins / Q000502:physiology; D001161:Arteriosclerosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002986:Clinical Trials as Topic; D004730:Endothelium, Vascular / Q000503:physiopathology; D005786:Gene Expression Regulation; D006801:Humans; D006946:Hyperinsulinism / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D007328:Insulin / Q000502:physiology; D007333:Insulin Resistance; D008077:Lipoproteins, LDL / Q000378:metabolism; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D008954:Models, Biological; D015337:Multicenter Studies as Topic; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D016328:NF-kappa B / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects / Q000502:physiology; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D015398:Signal Transduction; D019851:Thrombophilia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D014657:Vasculitis / Q000209:etiology / Q000503:physiopathology
D047228:Angiotensin II Type 1 Receptor Blockers; D000809:Angiotensins; D015815:Cell Adhesion Molecules; D007328:Insulin; D008077:Lipoproteins, LDL; D016328:NF-kappa B; D044140:Receptor, Angiotensin, Type 1; C099252:oxidized low density lipoprotein